BioCentury | Feb 13, 2020
Management Tracks

Head of digital, three other execs set to leave Sanofi as Hudson continues reorg

Five months into his tenure as CEO, Paul Hudson has trimmed Sanofi’s executive team back by four. The executives departing Sanofi (Euronext:SAN; NASDAQ:SNY) are EVP, Business Transformation Dominique Carouge; EVP, CMO and Chief Digital Officer...
BioCentury | Feb 11, 2020
Product Development

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

The Phase II/III DIAN-TU trial of Lilly’s solanezumab and Roche’s gantenerumab was always a long shot, given the previous late-stage failures of both agents in Alzheimer’s trials. Perhaps more surprising is that both compounds remain...
BioCentury | Feb 7, 2020
Product Development

Roche, PTC provide first look at pivotal SMA data in adults

Roche and PTC reported the first pivotal data for a spinal muscular atrophy therapy in adults with established disease on Thursday when they unveiled the detailed data supporting their bid for risdiplam to treat SMA...
BioCentury | Feb 5, 2020
Product Development

Biogen investors look ahead to Alzheimer’s after Tecfidera IP win

The U.S. Patent Trial and Appeal Board removed a major overhang for Biogen investors on Wednesday after ruling to uphold the validity of a patent covering blockbuster MS therapy Tecfidera dimethyl fumarate. The news sent...
BC Extra | Jan 30, 2020
Company News

As Spinraza’s sales level off, Biogen presses ahead with aducanumab plans

Although Biogen’s earnings report suggests sales of SMA therapy Spinraza have plateaued, the company signaled its continued optimism that FDA will approve another potential blockbuster, its Alzheimer’s disease treatment aducanumab. Revenues from Spinraza nusinersen dipped...
BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

A ramped up focus on CNS that has been long in the making could start to pay off this year for Roche, which has two programs slated for launch and four others with late-stage readouts...
BC Extra | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

Pfizer is hoping that discounts of 22-24% from reference drugs’ wholesale acquisition costs (WACs) will help it gain market share for three new or soon-to-be launched biosimilars, each of which will compete with at least...
BC Extra | Jan 23, 2020
Company News

With established foothold in Japan, Amgen takes over JV from Astellas

Amgen will take over full ownership of the 2013 JV it launched with Astellas in Japan but the two will continue to co-promote Amgen’s three drugs in the country. The U.S. biotech has used its...
BC Extra | Jan 23, 2020
Clinical News

Risdiplam hits again in FIREFISH, setting up oral option for SMA patients

As risdiplam inches closer to the market in spinal muscular atrophy, the oral candidate notched another win, hitting the primary endpoint in the Phase II/III FIREFISH study and setting up a new alternative for SMA...
Items per page:
1 - 10 of 4834
BioCentury | Feb 13, 2020
Management Tracks

Head of digital, three other execs set to leave Sanofi as Hudson continues reorg

Five months into his tenure as CEO, Paul Hudson has trimmed Sanofi’s executive team back by four. The executives departing Sanofi (Euronext:SAN; NASDAQ:SNY) are EVP, Business Transformation Dominique Carouge; EVP, CMO and Chief Digital Officer...
BioCentury | Feb 11, 2020
Product Development

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

The Phase II/III DIAN-TU trial of Lilly’s solanezumab and Roche’s gantenerumab was always a long shot, given the previous late-stage failures of both agents in Alzheimer’s trials. Perhaps more surprising is that both compounds remain...
BioCentury | Feb 7, 2020
Product Development

Roche, PTC provide first look at pivotal SMA data in adults

Roche and PTC reported the first pivotal data for a spinal muscular atrophy therapy in adults with established disease on Thursday when they unveiled the detailed data supporting their bid for risdiplam to treat SMA...
BioCentury | Feb 5, 2020
Product Development

Biogen investors look ahead to Alzheimer’s after Tecfidera IP win

The U.S. Patent Trial and Appeal Board removed a major overhang for Biogen investors on Wednesday after ruling to uphold the validity of a patent covering blockbuster MS therapy Tecfidera dimethyl fumarate. The news sent...
BC Extra | Jan 30, 2020
Company News

As Spinraza’s sales level off, Biogen presses ahead with aducanumab plans

Although Biogen’s earnings report suggests sales of SMA therapy Spinraza have plateaued, the company signaled its continued optimism that FDA will approve another potential blockbuster, its Alzheimer’s disease treatment aducanumab. Revenues from Spinraza nusinersen dipped...
BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

A ramped up focus on CNS that has been long in the making could start to pay off this year for Roche, which has two programs slated for launch and four others with late-stage readouts...
BC Extra | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

Pfizer is hoping that discounts of 22-24% from reference drugs’ wholesale acquisition costs (WACs) will help it gain market share for three new or soon-to-be launched biosimilars, each of which will compete with at least...
BC Extra | Jan 23, 2020
Company News

With established foothold in Japan, Amgen takes over JV from Astellas

Amgen will take over full ownership of the 2013 JV it launched with Astellas in Japan but the two will continue to co-promote Amgen’s three drugs in the country. The U.S. biotech has used its...
BC Extra | Jan 23, 2020
Clinical News

Risdiplam hits again in FIREFISH, setting up oral option for SMA patients

As risdiplam inches closer to the market in spinal muscular atrophy, the oral candidate notched another win, hitting the primary endpoint in the Phase II/III FIREFISH study and setting up a new alternative for SMA...
Items per page:
1 - 10 of 4834